Elutia Inc. reported its Q1 2026 earnings, with an EPS of -$0.17, missing the forecast of -$0.15 by 13.33%. However, revenue came in at $3.1 million, exceeding the expected $2.9 million by 6.9%.
Despite the revenue beat, the stock fell 4.76% in aftermarket trading, closing at $1. This decline reflects investor concerns over the EPS miss and widening net loss.
Management remains focused on the NXT-41X program, anticipating FDA clearance for NXT-41 in Q4 2026 and NXT-41X in H1 2027. Commercialization is targeted for H2 2027.
CEO Randy Mills highlighted the strategic pivot towards NXT-41X, emphasizing its potential in the breast reconstruction market. He also noted productive FDA interactions.
